Evolution of beta-lactamase inhibitors.
After the introduction of penicillin G into therapeutics, bacteria became increasingly resistant to this penicillin and subsequent beta-lactam antibiotics. The major cause of this resistance is beta-lactamase, an enzyme produced by the bacterium, that destroys the antibiotic before it reaches its target within the bacterial cell. One of the ways to combat this resistance has been the use of beta-lactamase inhibitors, which protect the antibiotic by inactivating the destructive enzyme before the antibiotic reaches the infection site. At present, at least two beta-lactamase inhibitors are in clinical use, clavulanic acid and sulbactam, that are effective against most beta-lactamases, although relatively inactive against class I beta-lactamases, the cephalosporinases. Newly developed beta-lactamase inhibitors, however, especially BRL-42715, show some promise against these enzymes.
Jackson
D
D
Department of Clinical Pharmacology and Therapeutics, Folkestone, Kent, Great Britain.
D000900:Anti-Bacterial Agents / Q000378:metabolism; D001419:Bacteria / Q000187:drug effects / Q000201:enzymology; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D013407:Sulbactam / Q000494:pharmacology*; D065093:beta-Lactamase Inhibitors
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D013407:Sulbactam